FDA Sees Drug Discovery Technology, Mergers Cutting Down On NDAs
Executive Summary
FDA believes novel drug discovery technologies are contributing to the reduction in "truly innovative applications," Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, said
You may also be interested in...
Pfizer Sees R&D Rebound, Says FDA Safety Reviews “Not Inappropriate”
Refinements to pharmaceutical industry pipelines during the Clinton healthcare reform era are about to pay off in a wave of new product launches, Pfizer CEO Hank McKinnell told investors at the Bear Stearns healthcare conference in New York City Sept. 17
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials